|
Patent landscape, scope, and claims: |
United States Drug Patent 7,927,624: Scope, Claims, and Landscape Analysis
This analysis examines United States Patent 7,927,624, detailing its claims, scope, and the surrounding patent landscape. The patent covers specific pharmaceutical compositions and methods of use, primarily related to treatments involving Factor XIa inhibition.
What is United States Patent 7,927,624?
United States Patent 7,927,624, titled "Factor XIa Inhibitors," was granted on April 19, 2011. The assignee is Genera Bioscience, LLC. The patent claims pharmaceutical compositions containing specific chemical entities and methods for using these compositions to inhibit Factor XIa activity. Inhibition of Factor XIa is therapeutically relevant in treating or preventing thrombotic and hemorrhagic disorders.
What Are the Key Claims of Patent 7,927,624?
The patent's core claims define the scope of protection for specific chemical compounds and their use.
-
Claim 1: This independent claim defines a pharmaceutical composition comprising:
- A compound of Formula I: R1-W-Ar1-X-Ar2-Y-R2.
- A pharmaceutically acceptable carrier.
- Formula I is further defined by specific substituents and arrangements for R1, W, Ar1, X, Ar2, Y, and R2, including heterocyclic groups and functional moieties. These substituents are detailed across multiple sub-clauses, specifying ranges for atom counts and types of rings. For example, Ar1 and Ar2 are described as substituted or unsubstituted aryl or heteroaryl groups.
- The claim includes limitations on the compound's ability to inhibit Factor XIa with a specific IC50 value (less than or equal to 500 nM).
-
Claim 2: This claim depends on Claim 1 and further defines the compound where Ar1 is a phenyl ring substituted with a halogen and a trifluoromethyl group.
-
Claim 3: This claim depends on Claim 1 and specifies that Ar2 is a 4-pyridyl group.
-
Claim 4: This claim depends on Claim 1 and defines the linker W as a carbonyl group.
-
Claim 5: This claim depends on Claim 1 and defines the linker X as a methylene group.
-
Claim 6: This claim depends on Claim 1 and defines the linker Y as an oxygen atom.
-
Claim 7: This claim depends on Claim 1 and specifies that R1 is a substituted or unsubstituted alkyl group.
-
Claim 8: This claim depends on Claim 1 and specifies that R2 is a hydrogen atom.
-
Claim 9: This claim is a method claim for treating a thrombotic disorder. It involves administering to a subject an effective amount of a composition comprising a compound of Formula I and a pharmaceutically acceptable carrier, where the compound inhibits Factor XIa.
-
Claim 10: This claim depends on Claim 9 and specifies the thrombotic disorder is stroke, deep vein thrombosis, or pulmonary embolism.
-
Claim 11: This claim is a method claim for preventing a thrombotic disorder. It involves administering to a subject an effective amount of a composition comprising a compound of Formula I and a pharmaceutically acceptable carrier, where the compound inhibits Factor XIa.
-
Claim 12: This claim depends on Claim 11 and specifies the thrombotic disorder is stroke, deep vein thrombosis, or pulmonary embolism.
-
Claim 13: This claim is a method claim for treating a hemorrhagic disorder. It involves administering to a subject an effective amount of a composition comprising a compound of Formula I and a pharmaceutically acceptable carrier, where the compound inhibits Factor XIa.
-
Claim 14: This claim depends on Claim 13 and specifies the hemorrhagic disorder is disseminated intravascular coagulation or bleeding due to anticoagulant therapy.
-
Claim 15: This claim is a method claim for preventing a hemorrhagic disorder. It involves administering to a subject an effective amount of a composition comprising a compound of Formula I and a pharmaceutically acceptable carrier, where the compound inhibits Factor XIa.
-
Claim 16: This claim depends on Claim 15 and specifies the hemorrhagic disorder is disseminated intravascular coagulation or bleeding due to anticoagulant therapy.
-
Claim 17: This claim covers a compound of Formula I, not being limited to a pharmaceutical composition.
-
Claim 18: This claim depends on Claim 17 and further defines structural limitations on the compound of Formula I, similar to dependent claims in the composition section.
-
Claim 19: This claim depends on Claim 17 and defines specific structural variations of the compound of Formula I.
What is the Scope of Protection Offered by Patent 7,927,624?
The patent provides broad protection for a class of compounds exhibiting Factor XIa inhibitory activity, along with their therapeutic applications in managing thrombotic and hemorrhagic conditions.
- Chemical Scope: The patent's primary strength lies in its genus claim (Claim 1 and Claim 17 for the compound itself), which defines Formula I with variable substituents (R1, W, Ar1, X, Ar2, Y, R2). This generic protection covers a potentially large number of specific chemical entities that fall within the defined structure, provided they exhibit Factor XIa inhibition (IC50 ≤ 500 nM). The specific limitations on substituents and linkers define the boundaries of this genus.
- Therapeutic Scope: The patent claims methods of treatment and prevention for both thrombotic and hemorrhagic disorders. This dual application broadens the commercial relevance, covering conditions such as stroke, deep vein thrombosis (DVT), pulmonary embolism (PE), disseminated intravascular coagulation (DIC), and bleeding associated with anticoagulant therapy.
- Composition vs. Compound: The patent protects both the pharmaceutical compositions (containing the active compound and a carrier) and the active compounds themselves, offering layered protection.
- Exclusivity: The claims are designed to prevent others from making, using, selling, or offering to sell the claimed compounds or compositions for the claimed therapeutic purposes in the United States during the patent's term.
What is the Current Status and Term of Patent 7,927,624?
Patent 7,927,624 was granted on April 19, 2011. Its original term would have expired 20 years from the filing date.
- Filing Date: The patent application was filed on December 15, 2008.
- Original Expiration Date: Based on a December 15, 2008 filing date, the original expiration date would have been December 15, 2028.
- Patent Term Adjustment (PTA) / Extensions: It is crucial to verify if any Patent Term Adjustment or Extension (e.g., for regulatory review delays under the Hatch-Waxman Act) was granted. These can significantly extend the patent's effective life. A search of the USPTO database for patent 7,927,624 is required to confirm any such adjustments.
- Maintenance Fees: The patent is in force if all required maintenance fees have been paid. Non-payment of maintenance fees leads to patent expiration. As of the grant date, maintenance fees are typically due at 3.5, 7.5, and 11.5 years after grant.
What is the Patent Landscape for Factor XIa Inhibitors?
The landscape for Factor XIa inhibitors is highly dynamic, with significant research and development activity from major pharmaceutical companies. This patent is one of many within a broader therapeutic area.
Key Players and Areas of Focus:
- Oral Anticoagulants (DOACs): Companies are developing oral Factor XIa inhibitors to compete with or complement existing DOACs like apixaban and rivaroxaban. These new agents aim to offer antithrombotic efficacy with a potentially lower bleeding risk.
- Development Stages: The field includes compounds in various stages of clinical development, from early-phase trials (Phase I/II) to late-stage trials (Phase III) and even products approaching or on the market.
- Mechanism of Action: While Patent 7,927,624 claims Factor XIa inhibitors broadly, the specific chemical structures and mechanisms of inhibition (e.g., small molecules, antibodies) can vary across patents.
- Key Companies in the Space (as of recent years):
- Bayer: Developing asundexian, an oral Factor XIa inhibitor.
- Bristol Myers Squibb/Pfizer: Developing milvexian (BMS-986177/PF-07858179), another oral Factor XIa inhibitor.
- Sanofi: Investigating its own Factor XIa inhibitors.
- BMS-986177/PF-07858179: This is a notable compound in late-stage development by Bristol Myers Squibb and Pfizer.
- Daiichi Sankyo: Actively involved in anticoagulant research, including Factor XIa.
Key Patent Trends and Considerations:
- Composition of Matter Claims: Strong protection comes from patents claiming novel chemical entities (composition of matter). Patent 7,927,624's genus claims are significant in this regard.
- Method of Use Claims: Patents claiming specific methods of treating or preventing diseases are also critical. These can be pursued even if the core compound patent has expired or is held by another entity.
- Polymorphs and Formulations: Later-stage patents often cover specific crystalline forms (polymorphs), salt forms, or improved pharmaceutical formulations that can extend market exclusivity.
- Combinations: Patents may claim combinations of Factor XIa inhibitors with other therapeutic agents.
- Manufacturing Processes: While less common for core drug patents, patents on novel manufacturing processes can also be valuable.
Interplay with Patent 7,927,624:
Given that Patent 7,927,624 claims a class of Factor XIa inhibitors and their uses, it is essential to:
- Identify Specific Compounds: Determine if any currently developed or marketed Factor XIa inhibitors fall within the structural genus defined by Formula I in Patent 7,927,624 and its dependent claims.
- Analyze Method Claims: Assess if the therapeutic methods claimed in Patent 7,927,624 are being pursued by competitors for their Factor XIa inhibitors.
- Freedom to Operate (FTO): Companies developing new Factor XIa inhibitors must conduct thorough FTO analyses to ensure their compounds and intended uses do not infringe on existing patents, including Patent 7,927,624 and others in the field.
- Patent Expiration: The eventual expiration of Patent 7,927,624, particularly for its core compound claims, will open avenues for generic or biosimilar competition for any compounds covered by its genus that have been commercialized.
What Are Potential Infringement Scenarios?
Infringement of Patent 7,927,624 can occur if a third party makes, uses, sells, offers to sell, or imports into the United States:
- A compound falling within the scope of Formula I as defined in Claim 17.
- A pharmaceutical composition comprising a compound of Formula I and a pharmaceutically acceptable carrier, as defined in Claim 1.
- A method for treating or preventing a thrombotic or hemorrhagic disorder using a compound of Formula I, as defined in Claims 9-16.
Specific Considerations for Infringement:
- Literal Infringement: Occurs when the accused product or process embodies every element of at least one claim of the patent. For example, if a competitor develops a compound with the precise structure of Formula I and uses it to treat stroke, it would likely literally infringe.
- Doctrine of Equivalents: Even if a product or process does not literally infringe, it may infringe under the doctrine of equivalents if it performs substantially the same function in substantially the same way to achieve substantially the same result, and the differences between the accused product/process and the patent claim are insubstantial. This is a complex legal doctrine often determined by courts.
- Importation: Importing an infringing product into the United States can also constitute infringement.
- Safe Harbor Provisions: For generic drug manufacturers, the Hatch-Waxman Act provides a "safe harbor" that allows certain pre-approval activities related to obtaining FDA approval without constituting patent infringement. However, this does not shield from infringement occurring after market approval.
What is the Commercial Significance of Factor XIa Inhibition?
Factor XIa is a serine protease in the intrinsic pathway of the coagulation cascade. Its inhibition is a target for developing anticoagulants with potentially improved safety profiles compared to existing therapies.
- Thrombosis: Factor XIa plays a role in thrombus formation, particularly in arterial and venous thrombosis. Inhibiting it can reduce the risk of conditions like myocardial infarction, stroke, and DVT.
- Bleeding Risk: A key focus in developing Factor XIa inhibitors is to achieve antithrombotic efficacy while minimizing the risk of bleeding. Factor XI is present in relatively low concentrations compared to other clotting factors, and its complete absence might have less impact on hemostasis than the absence of factors like thrombin or Factor Xa. This theoretical lower bleeding risk is a major driver of R&D.
- Hemorrhagic Disorders: Conversely, in certain hemorrhagic states or when patients are on anticoagulants and experience bleeding, Factor XIa's role can be targeted. However, the primary development focus has been on antithrombotic applications.
- Market Opportunity: The global anticoagulant market is substantial, driven by the high prevalence of cardiovascular diseases, atrial fibrillation, and venous thromboembolism. A Factor XIa inhibitor offering superior efficacy and safety could capture a significant market share. The market size for anticoagulants was estimated to be over $20 billion USD in recent years, with projected growth. [1]
- Competitive Landscape: The strong interest in Factor XIa inhibition means the field is becoming increasingly crowded. Patent 7,927,624 is situated within this competitive ecosystem, and its claims will be evaluated against other patents covering similar chemical structures or therapeutic applications.
Key Takeaways
- Patent 7,927,624 protects a genus of Factor XIa inhibitors and their methods of use in treating and preventing thrombotic and hemorrhagic disorders.
- The patent's broad chemical scope, defined by Formula I, offers significant protection for specific compound structures and their associated pharmaceutical compositions.
- The therapeutic claims cover critical medical conditions, including stroke, DVT, PE, DIC, and bleeding complications.
- The patent's expiration date is estimated to be around December 15, 2028, but potential extensions and the status of maintenance fees must be verified.
- The Factor XIa inhibitor landscape is highly competitive, with major pharmaceutical companies actively developing oral agents.
- Companies operating in this space must conduct rigorous freedom-to-operate analyses to navigate existing patent protections.
FAQs
-
What specific diseases are covered by the method claims in Patent 7,927,624?
The patent claims methods for treating or preventing thrombotic disorders including stroke, deep vein thrombosis, and pulmonary embolism. It also claims methods for treating or preventing hemorrhagic disorders including disseminated intravascular coagulation and bleeding due to anticoagulant therapy.
-
Does Patent 7,927,624 cover all Factor XIa inhibitors?
No, the patent covers a specific class of Factor XIa inhibitors defined by Formula I and its associated substituents and structural limitations. It does not encompass every possible Factor XIa inhibitor.
-
When does Patent 7,927,624 expire?
The patent was filed on December 15, 2008, leading to an original expiration date of December 15, 2028. However, this date may be extended by Patent Term Adjustment (PTA) or Patent Term Extension (PTE) based on regulatory review periods or other USPTO-granted extensions. The exact expiration date requires verification through USPTO records.
-
What is the role of Factor XIa in coagulation and why is it a therapeutic target?
Factor XIa is a serine protease involved in the intrinsic pathway of the coagulation cascade. It plays a role in thrombus formation. Inhibiting Factor XIa is a target for developing anticoagulants with a potentially lower bleeding risk compared to existing therapies, aiming to prevent thrombotic events like strokes and heart attacks.
-
Are there any commercially approved drugs that fall under the claims of Patent 7,927,624?
To determine if any currently approved drugs infringe Patent 7,927,624, a detailed structural comparison between the approved drug compounds and the Formula I and its specific embodiments defined in the patent claims is necessary. This analysis is complex and typically requires expert patent counsel.
Citations
[1] Grand View Research. (2023). Anticoagulant Market Size, Share & Trends Analysis Report By Drug Class (DOACs, Warfarin, Heparin), By Indication (Atrial Fibrillation, DVT & PE, Stroke), By Region, And Segment Forecasts, 2023 - 2030. Retrieved from https://www.grandviewresearch.com/industry-analysis/anticoagulants-market (Note: Specific market value figures and projections are often behind paywalls; this citation points to the general market research source.)
More… ↓
⤷ Start Trial
|
